קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

viatris hrvatska d.o.o., koranska 2, zagreb, hrvatska - salmeterolksinafoat flutikazonpropionat - stlačeni inhalat, suspenzija - 25 mikrograma + 250 mikrograma - urbroj: jedna odmjerna doza (potiskom preko ventila) sadrži: 25 mikrograma salmeterola (u obliku salmeterolksinafoata) i 250 mikrograma flutikazonpropionata. to odgovara isporučenoj dozi (preko nastavka za usta) od 21 mikrograma salmeterola i 220 mikrograma flutikazonpropionata

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinom, ne-malih stanica pluća - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 100 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 100 mikrograma flutikazonpropionata

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 250 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 500 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 500 mikrograma flutikazonpropionata

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

salvus d.o.o., toplička cesta 100, donja stubica, hrvatska - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 250 mikrograma - urbroj: jedna doza sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 250 mikrograma flutikazonpropionata

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

salvus d.o.o., toplička cesta 100, donja stubica, hrvatska - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 500 mikrograma - urbroj: jedna doza sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 500 mikrograma flutikazonpropionata

קרואטיה - קרואטית - HALMED (Agencija za lijekove i medicinske proizvode)

salvus d.o.o., toplička cesta 100, donja stubica, hrvatska - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 100 mikrograma - urbroj: jedna doza sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 100 mikrograma flutikazonpropionata

האיחוד האירופי - קרואטית - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

בוסניה והרצגובינה - קרואטית - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

providens d.o.o. sarajevo - Беклометазон, formoterol - stlačeni inhalat, otopina - 100 µg/1 doza+ 6 µg/1 doza - 1 doza sadrži: 100 µg beklometazona (u obliku beklometazon dipropionata) i 6 µg formoterola (u obliku formoterol fumarat dihidrata)